Evaluation of the Cohort Size in Phase I Dose Escalation Trials Based on Laboratory Data-Reference-Cited by-同舟云学术

Evaluation of the Cohort Size in Phase I Dose Escalation Trials Based on Laboratory Data

Published:2003-05 Issue:5 Volume:43 Page:470-476
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Buöen Camilla,Holm Sture,Thomsen Mikael S.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference38 articles.

1. Assessment of the cohort size for safety evaluation of one dosing level in first human dose trials;Buöen;J Clin Pharmacol,2002

2. Estimating the starting dose for entry into humans: principle and practice;Reigner;Eur J Clin Pharmacol,2002

3. Selection of initial dose and dose-ranging for first-in-human studies: a hidden, unnecessary or unresolved issue;Hernández-López;Pharmacol Toxicol,2001

4. Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectives;Cutler;J Clin Pharmacol,1997

5. Defining the maximum tolerated dose: an update;Cutler;J Clin Pharmacol,2000

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Feasibility of Intradiscal Administration of Matrilin-3-Primed Adipose-Derived Mesenchymal Stromal Cell Spheroids for Chronic Discogenic Low Back Pain: Phase 1 Clinical Trial;International Journal of Molecular Sciences;2023-11-27

2. Using the TI.VA algorithm to titrate the depth of general anaesthesia: a first-in-humans study;BJA Open;2023-09

3. Improving rigor and reproducibility in nonhuman primate research;American Journal of Primatology;2021-09-20

4. Phase 1 Clinical Trials of Small Molecules: Evolution and State of the Art;Reviews on Recent Clinical Trials;2021-07-16

5. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study;The Lancet Infectious Diseases;2020-11